A target price of $63.285 has been placed by Wall Street analysts. They have used the mean consensus estimate from the 14 research firms, which have had a recent issue of reports on the stock to arrive at this number. But how was the average broker recommendation come about? It is the arithmetical standard of the individual ratings from the sell-side analysts, which produce a Consensus Analyst Rating for every stock.
The stock’s ranking 2.5, which is on the basis of 14 broker recommendations is done through the use of a 1 to 5 scale whereby 1 and 5 represents a Strong Buy and a Strong Sell respectively. The most bullish of the 14 analysts who have issued estimates thinks that the stock is reaching $100 within the next 12 months. Nonetheless, most conservative have a different opinion, that the stock will be at $48 within the year.
Earnings per share expected from Bristol-Myers Squibb Company (NYSE:BMY) by analyst for the current fiscal quarter are $0.65. This translates to the consensus mean estimate, whose basis is on the individual covering sell-side analysts’ reported numbers. $0.77 was reported by the company as its last earnings for the period ending on 2016-09-30. Away from the consensus estimate, the reported number was 0.12, which could also be referred to as a surprise factor of 18.46.
The long term growth prospects of the company have a different outlook. According to the sell-side analysts, the current year has a consensus mean earnings per share estimate of $2.95. While the high end estimate for this time frame is at $3.06, the low one is $2.79.